Bodenstedt Matthias's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Oct 9, 2025
- Accession no.
- 0001213900-25-097594
- Filed
- Oct 9, 2025
- Trade date
- Oct 8, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $98.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bodenstedt MatthiasCIK 0001920545 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | Class A ordinary shares, par value $0.0001 per share | PPurchaseAcquired | +10,870 | $9.09F1 | +$98,808.3 | 627,536 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $9.085 to $9.091244. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.